. Influence of initial insulin dosage on blood glucose dynamics of children and adolescents with newly diagnosed type 1 diabetes mellitus. Pediatric Diabetes 2017: 18: 196-203. Objective: To investigate the effect of initial insulin dosage on blood glucose (BG) dynamics, β-cell protection, and oxidative stress in type 1 diabetes mellitus. Methods: Sixty newly diagnosed type 1 diabetes mellitus patients were randomly assigned to continuous subcutaneous insulin infusions of 0.6 ± 0.2 IU/kg/d (group 1), 1.0 ± 0.2 IU/kg/d (group 2), or 1.4 ± 0.2 IU/kg/d (group 3) for 3 wk. BG was monitored continuously for the first 10 d and the last 2 d of wk 2 and 3. A total of 24-hour urinary 8-iso-PGF2α was assayed on days 8, 9, and 10. The occurrence and duration of the honeymoon period were recorded. Fasting C-peptide and glycosylated hemoglobin (HbA1c) were assayed after 1, 6, and 12 months of insulin treatment. Results: BG decreased to the target range by the end of wk 3 (group 1), wk 2 (group 2), or wk 1 (group 3). The actual insulin dosage over the 3 wk, frequency of hypoglycemia on wk 1 and 2, and median BG at the end of wk 1 differed significantly, but not 8-iso-PGF2α and the honeymoon period in the three groups. No severe hypoglycemia event was observed in any patient, but there was significant difference in the first occurrence of hypoglycemia. Conclusions: Differences in initial insulin dosage produced different BG dynamics in wk 1, equivalent BG dynamics on wk 2 and 3, but had no influence on short-and long-term BG control and honeymoon phase. The wide range of initial insulin dosage could be chosen if guided by BG monitoring.
Type 1 diabetes mellitus (T1DM) is an autoimmune disease caused by T cell-mediated pancreatic β cell impairment (1) . When diagnosed with T1DM, patients must be immediately treated with insulin to avoid metabolic decompensation, diabetic ketoacidosis (DKA), and long-term chronic complications (2, 3) . Keeping pancreatic β cell function in T1DM patients could result in better BG control, decrease glycosylated hemoglobin (HbA1c) levels, minimize BG fluctuations, and risks of long term complications, such as risk of retinopathy and kidney disease (4, 5) . Keenan et al. reported there was residual endogenous insulin secretion in 67.4% T1DM patients with a disease duration of 50 yr or longer, and in nine postmortem examinations of pancreatic tissue, insulin positive cells were found (6) . Rother et al. also reported residual insulin secretion by pancreatic β cells in cases of long-standing T1DM, that had been suppressed by exogenous insulin, which suggests that pancreatic β cells are protected by exogenous insulin (7) .
Influence of initial insulin dosage
Several studies in adult T2DM research have confirmed that if the BG level reaches a normal range in the early period, it will protect β cells from being destroyed (8, 9) , but similar studies are few in children and adolescents with T1DM. Higher initial insulin dosage could rapidly decrease BG, but will it be better protecting β cells as with T2DM in adult or would it worsen BG fluctuations and thereby greatly damaging β cells? This needs to be studied.
Various initial insulin dosages for newly diagnosed T1DM patients are described in the published literature. Through communications with various diabetes centers, we found that some use an initial insulin dosage of 2.0 IU/kg/d, even though some guidelines recommended only 0.5-1.0 IU/kg/d for children with T1DM and 0.2-0.5 IU/kg/d for children with type 2 diabetes mellitus (T2DM) (10) . The advantages and disadvantages of varied initial insulin dosages used in clinical practice remain unclear. This study investigated the influence of three different initial insulin dosages on BG control in 60 children and adolescents who were newly diagnosed with T1DM. Dynamic BG changes were followed by continuous glucose monitoring. BG control status in the acute phase, safety (i.e., hypoglycemia occurrence), BG fluctuation, oxidative stress levels, honeymoon period, C-peptide level, and BG control at 1-yr of duration were evaluated.
Methods

Ethics
The Ethics Committee of Beijing Children's Hospital approved the study protocol. All participants and their guardians gave written informed consent after the protocol and research methods were fully explained.
Subjects
Sixty newly diagnosed T1DM patients [Diagnostic standard of T1DM According to ISPAD Clinical Practice Consensus Guidelines for Diabetes in Childhood and Adolescence in 2014 (11)] were enrolled sequentially and assigned, using a table of random numbers, to an daily initial insulin dosage (including basal and bolus insulin, and insulin dosage of the two part is equal) of 0.6 U/kg/d (group 1), 1.0 U/kg/d (group 2), or 1.4 U/kg/d (group 3). Patients were eligible for inclusion in the study if they were 0-18 yr and newly diagnosed with T1DM. Patients were excluded if they had been treated with insulin for more than 7 d; had severe liver or kidney damage, cardiac insufficiency, severe trauma or infection, accompanying diseases affecting sugar metabolism such as adrenal diseases or other chronic systemic diseases such as asthma or chronic kidney diseases and so on.
Methods
All T1DM patients were treated with a continuous subcutaneous insulin infusion (CSII) for 3 wk, and BG levels were monitored continuously for the first 10 d and then on the last 3 d of each week (continual glucose monitoring system, CGMS; Medtronic Mini Med, Medtronic Corporation, Po Indianapolis City, MN, USA). Patients experiencing diabetic ketosis (DK) or DKA were treated with CSII and were included after DKA correction. Implantation of the CGMS sensors was performed by professional nurses. Fingertip BG (ONETOUCH Ultra BG meter, Johnson & Johnson, New Buren Zwick, NJ, USA) were checked seven times daily (03:00, 07:00, and 10:00 hours; 01:00, 04:00, 07:00, and 09:00 hours) and the results were exported to the Minimed CGMS software system for calibration and analysis. A professional dietitian catered the patient diets. Energy uptake and exercise expenditure were controlled to maintain relatively constant levels. The total daily calorie needs of the children were determined as: age (yr) × (70-100) + 1000 kcal. Patients performed light physical exercise (i.e., walking for 15 min) in the hospital ward after each meal and before sleeping.
The 24-h urine specimens were collected at 08:00 hours on days 8, 9, 10 of CGMS monitoring. Resting urine was evacuated and discarded when timing began, and the final urine was collected in a clean container when timing ended. During the 3 d of urine collection, urine volume of each 24-h period was recorded, 10 mL of the urine was stored at −80
• C until laboratory testing. Average data of the 3 d were calculated for the comparison.
Insulin dosage adjustment protocol
The dosage range tolerance of each group was ±0.2 U/kg/d. In group 1, blood and urine ketones were assayed if the BG exceeded 20 mmol/L, and if there was no evidence of DKA, the insulin dosage was not increased but kept at 0.6 ± 0.2 IU/kg/d. In group 3, insulin dosage was decreased following two episodes of hypoglycemia (i.e., fingertip BG <3.9 mmol/L). If fasting BG was low, the base rate was decreased by 10% at 2 h before hypoglycemia occurred. If BG was low 2 h after meals, the large insulin dosage before the meals was decreased by 10%, maintaining the group 3 insulin dosage of 1.4 ± 0.2 U/kg/d. If continuous hypoglycemia occurred in group 3 patients on the second and third weeks, the insulin dosage was decreased to that of group 2. If there were no episodes of hypoglycemia, insulin dosage was not modified. The insulin dosage was maintained at 1.0 ± 0.2 U/kg/d in group 2, but with adjustments similar to those described above for group 3. 
Blood glucose monitoring
Data collected by the CGMS over the first 10 d and the last 2 d of the second and third weeks were evaluated. CGMS datasets that included more than 230 BG measurements within a 24-hour period were assumed to give an accurate picture of changes in BG concentration (i.e., dynamics). The parameters that were evaluated included the median BG (MBG) level recorded by the CGMS within each 24-h period and the BG fluctuation, which was described as the mean standard deviation of BG (SDBG) recorded by the CGMS within each 24-h period. SDBG reflects the extent of deviation from the mean blood glucose level and illustrates the dynamic dispersion of daily blood glucose levels (12) . The mean amplitude of glycemic excursions (MAGE) provides the mean value of all the amplitudes of glycemic excursions that exceed one SDBG (12) . It can make up for the SDGB shortcoming of not distinguishing between major and minor glycemic excursions. The frequency of hypoglycemia (HF) occurrences was used to evaluate the safety of the study protocol.
Laboratory assays
Urinary 8-iso-prostaglandin (8-iso-PG) F2α, a marker of oxidative stress levels, was determined using enzyme linked immunosorbent assay (ELISA) using a fully automatic multifunction microplate reader (Labsystems Dragon Multiskan MK3; Thermo Scientific, MA, USA). The minimum detectable concentration was 2.7 pg/mL; intra-and interassay coefficients of variation were both ≤5%. Urinary creatinine (Cr) was measured with the two-point fixed time endpoint method using an automated biochemical analyzer (Toshiba 120, Japan; reagents from Prodia Diagnostics, Freiburg, Germany). The relative deviation for detection accuracy was within ±10%. The urine samples collected during the study were stored at −80
• C, and all were assayed at the same time. Fasting BG, C-peptide, and HbA1c were measured by the hexokinase method (Olympus AU2700 automatic biochemical analyzer, Olympus Corporation, Tokyo, Japan), solid phase, competitive binding chemiluminescence enzyme immunoassay (IMMULITE analyzer, Diagnostic Products Corporation, Los Angeles, California, USA), and ion exchange HPC (SYS-MEX glycosylated hemoglobin automatic analyzer, Sysmex America Corporation, Lincolnshire, Illinois, USA), respectively. The BG assays were done at the radio-immune center and biochemical laboratory of our hospital.
Follow-up and monitoring
The time of occurrence and duration of the honeymoon period, with stable BG at an insulin dosage ≤0.5 U/kg/d and HbA1c <7% was recorded (13) . When missing data was less than 20%, we believe that the data of the group was valid. Patients were evaluated at 2 wk; 1, 3, 6, and 12 month after the initiation of insulin treatment. HbA1c and hepatorenal function were assayed, and routine urine tests were performed at each re-evaluation. BG monitoring, insulin usage, and the occurrence of clinically significant events such as severe hypoglycemia were recorded in detail.
Statistical analysis
Normally distributed data were reported as means ± SD, and data with skewed distributions were reported as medians. Multiple group comparisons were performed by a rank-sum test (Kruskal-Wallis analysis of variance method). Comparison between two groups was performed by Fisher's least significant difference (LSD) method. p < 0.05 was considered to be statistically significant. Data analysis was performed by Statistical Product and Service Solutions 17.0 software (spss, International Business Machines Corporation, Armonk, NY, USA).
Results
Patient characteristics and dose adjustments
The baseline characteristics of the study patients are shown in Table 1 . The three groups did not differ At the end of wk 3, no patients remained in group 3, and there were only nine in group 2 ( Table 2) . At the end of wk 3, group 1 included 16 patients from group 2 (80% of group 2), and 15 patients from group 3 (75% of group 3). Of the nine patients in group 2 at the end of wk 3, five were from Group 3 (25% of group 3).
BG dynamics
The BG dynamics of the study patients during the first 10 d are shown in Fig. 1 . The high insulin dosage (1.4 ± 0.2 U/kg/d) decreased BG significantly more rapidly than the low dosage (0.6 ± 0.2 U/kg/d), but differences between the medium and high dosage were not significant. There were no differences in BG dynamics among the three groups at the end of wk 2 and 3 ( Fig. 2) showing that the effects of an initial high insulin dosage disappeared as the treatment period was extended. The BG dynamics results reveal that high BG persisted longer in group 1 than in the other groups even though BG levels were almost the same in all groups at baseline.
BG fluctuation, CGMS data, and fingertip blood glucose monitoring
Although the insulin dosages in groups 1 and 3 were statistically different (p < 0.01 or p < 0.05) over the 3 wk, MBG was the only measure of BG fluctuation that was significantly (p < 0.01) higher in group 1 than it was in groups 2 and 3 in the first week (see Table S1 , Supporting Information).
In wk 2 and 3, no significant differences in MBG were observed in the three groups. No significant between-group differences were observed in the other indices, including SDBG, MAGE, and 8-iso-PGF2α/Cr (p > 0.05). Insulin dosage thus did not influence oxidative stress levels in this patient sample. Hypoglycemia was significantly more frequent in group 3 than in group 1 in wk 1 (p > 0.01) and 2 (p > 0.05), but not in wk 3 (p > 0.05). The CGMS data in Table 3 , show that hypoglycemia occurred in group 3 on the first and second day after treatment began, which was significantly (p < 0.001) sooner that it occurred in group 1. However, no episodes of severe hypoglycemia were observed. Fingertip BG was significantly lower (P<0.001) in group 3 than in group 1 on the first 2 d and the end of wk 1 and 2. However, there were no significant differences in fingertip BG among the three groups at the end of wk 3 (Fig. 3) . These results suggest that although a high initial insulin dosage increased the frequency of hypoglycemia, it is safe when insulin dosage is adjusted at an appropriate time.
When patients of the group 3 were stratified by age into young (≤9 yr of age, 10 patients) and an old (>9 yr of age, 10 patients) subgroups, it was found that the insulin dosage in wk 2 and 3 was significantly lower in the young patients than in the Table S2 ).
Honeymoon periods
The characteristics of the honeymoon period, including the time when they began and their duration were similar in the three groups (Fig. 4 ). There were also no significant between-group differences in fasting C-peptide and HbA1c (Fig. 5) , which are biochemical indices influenced by insulin treatment. Seen from Fig. 5 , HbA1c of all three groups was less than 7.5% at 6 months, which reached the target established by the ISPAD guideline. It was in the 12th month that the HbA1c values of the three groups was between 7.5 and 8.5%, that patients went through the honeymoon period; probably because in the Chinese medical system, patients either went to visit the doctor to get medical orders at site or managed BG by themselves. If their parents could not master the skills of adjusting insulin, they might they might not have been able to A B adjust the insulin dosage in a timely manner. This should not have affected the conclusion, because this trail was a random design with equal opportunity for patient interference. Follow-up results performed at 1, 6, and 12 months after the start of treatment did not reveal an insulin dosage that was more protective of residual β cell function than the others.
Discussion
T1DM is a serious health problem that often occurs in childhood and T1DM patients require lifelong insulin treatment. Therefore, proper insulin dosing is crucial to successful treatment. The available guidelines do not take into account the differences in BG dynamics that occur at different insulin dosages. In this study, high BG persisted longer at the low dosage group, BG decreased more quickly in higher insulin dosage group and the occurrence of mild hypoglycemia increased, but severe hypoglycemia was not observed.
The high dosage used in this study (1.4 ± 0.2 U/kg/d) decreased BG more quickly than the low dosage group (0.6 ± 0.2 U/kg/d), but it also induced more hypoglycemic events. After 1 wk of treatment, the insulin dosage of groups 1 (0.6 ± 0.2 U/kg/d) and 2 (1.0 ± 0.2 U/kg/d) remained unchanged, but four patients in group 3 were adjusted to the group 1 dosage and two were adjusted to the group 2 dosage. After 3 wk of treatment, 80% of the patients in group 2 and 75% in group 3 were adjusted to the group 1 dosage and the other 25% of group 3 patients were adjusted to group 2 dosage. Only one patient remained in group 3 at the end of wk 2. None was remaining in group 3 at the end of wk 3, only 9 in group 2, and 44 patients (73%) were in group 1. Five patients were on an insulin dosage of <0.4 U/kg/d. These results reveal that the appropriate initial insulin dosage varies widely among patients, and that approximately 90% of patients can tolerate higher insulin dosage for 2 wk.
Historically, high doses of insulin have been used to treat DKA, but there is evidence that the survival rate can be increased by using a low insulin dosage (14-16). Cemeroglu et al. reported that adult guidelines are not suitable for children, and that age should be considered when calculating insulin dosage (17) . Our clinical experience in diagnosis and treatment of more than 2000 T1DM patients is that most patients experience a honeymoon period after 3-4 wk of insulin treatment even without frequent BG monitoring and adjustment of insulin dosage. One would expect a high-insulin dosage to decrease BG quickly, but is the high dosage also likely to induce severe adverse effects? In this study, BG was closely monitored during insulin treatment, and no severe hypoglycemia events were observed. The first hypoglycemia instance occurred on day 2 in group 1, and on day 1 in groups 2 and 3, while the median days of first hypoglycemia occurrence were on 10.3, 4.8, and 4.7 d, respectively.
During the first week, hypoglycemic frequency was significantly lower in group 1 patients than in the other two groups (0, 8, and 14 instances, respectively). These results indicate that a high initial insulin dosage eliminated hyperglycemia quickly, but it resulted in early and more frequent hypoglycemia. To avoid symptomatic and asymptomatic hypoglycemia, the BG of patients given relatively high initial dosage needs to be monitored frequently. Although a high insulin dosage shortened the duration of hyperglycemia, the time to the beginning of the honeymoon period was not shortened. Hyperglycemia persisted longer in group 1 (0.6 ± 0.2 U/kg/d) patients, nevertheless it was well controlled within 3 wk. Also, the honeymoon period duration was similar to those in the other two groups. A low initial dosage has low hypoglycemic risk, and it is safer for patients whose BG monitoring is unavailable. And low initial dose is more practical for less experienced physicians.
Although large fluctuations in BG are associated with endothelial cell dysfunction in adult T2DM patients, the evidence is less clear in T1DM patients (18, 19) . In a previous study in T1DM patients, we found that BG fluctuations were related to oxidative stress (20) , and oxidative stress is strongly associated with development of vascular complications (21) . A study in children with T1DM reported that hypoglycemia rather than BG fluctuation was correlated with vascular dysfunction (22) . BG fluctuation, determined by seven daily measurements, was found to be a predictive marker of peripheral neuropathy, but not retinopathy, renal lesions, or vascular sclerosis lesions (23, 24) . Early treatment with CSII can decrease BG fluctuation (25, 26) and improve vascular function compared with multiple daily injections (MDI) (25) . We confirmed that children who converted to MDI/CSII regimens soon after T1DM onset achieved better BG control more rapidly than children treated by twice-daily insulin injections (27). After 6 months, however, HbA1c levels in children on the different regimens did not show any difference. It seems that the best therapeutic strategies will depend on the regimen and the implementation of these regimens (28) . BG fluctuation is an important factor which needs to be focused on during treatment of T1DM, therefore, in this study, we observed the BG excursion in the first 10 d after insulin treatment. It revealed that a higher insulin dosage decreased BG more quickly. In the three study groups, MBG, but not SDBG and MAGE, differed significantly. The BG fluctuations did not affect oxidative stress levels at the end of wk 1. Consequently, we deduced that differences in initial insulin dosage would have little direct influence on microvascular complications. Furthermore, there were no significant differences in the frequency and duration of honeymoon periods, fasting C-peptide level, or BG control among the three groups. It thus seems that the high initial insulin dosage had no protective effect on pancreatic β cells, which is similar to another study (29) .
We found that age had a significant influence on insulin tolerance, and in general, older patients tend to be tolerant to increased insulin dosage. Also, BG fluctuation and oxidative stress levels were not statistically different between young patients and those older than 9 yr. Larger studies are needed to study the responses of T1DM patients of different ages to different initial insulin dosages. Better understanding of how age affects response will help ensure choosing a safe and effective initial insulin dosage to guide clinical treatment.
Conclusions
We studied the security in the aspects of both BG and oxidative stress when different initial insulin dosages were used, but we did not get proof of protecting β cells effectively with high dose instead of increasing the chances of hypoglycemia. The CGMS used to track BG fluctuations following CSII of three different initial insulin dosages revealed the differences in the speed of achieving glycemic control. Fingertip BG and CGMS monitoring were both effective for monitoring hyper-and hypoglycemia, but CGMS was able to detect asymptomatic hypoglycemia. The study demonstrates that an initial insulin dosage from 0.4 to 1.6 U/kg was safe and effective in newly diagnosed children with T1DM when combined with appropriate BG-monitoring frequency, suggesting the low dose may be chosen if adequate self-monitoring of blood glucose is unavailable. the online version of this article: Table S1 . Blood glucose (BG) fluctuation and urine 8-iso-PGF2α concentration in the three study groups. Table S2 . Insulin dosage, blood glucose (BG) fluctuation, and oxidative stress index by age.
